Pfizer Recalls
134 recalls on record in the United States
Pfizer Recalls Nurtec ODT Prescription Drugs Due to Failure to Meet Child Resistant Packaging Requirement; Risk of Poisoning
None reported
View recall details →
PFIZER INC recalls Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL)
Lack of Assurance of Sterility.
View recall details →
PFIZER INC recalls Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50
Lack of Assurance of Sterility.
View recall details →
Pfizer recalls Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-cou
Subpotent drug
View recall details →
Pfizer Inc. recalls Bicillin L-A (penicllin G benzathine injectable suspension),
CGMP Deviations; particulates identified during visual inspection
View recall details →
Pfizer Inc. recalls Bicillin L-A (penicillin G benzathine injectable suspension)
CGMP Deviations; particulates identified during visual inspection
View recall details →
Pfizer Inc. recalls DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL
Discoloration; discolored solution from cracked vials
View recall details →
Pfizer Inc. recalls Labetalol Hydrochloride Injection, USP, 20 mg/4 mL (5 mg/mL)
Lack of Assurance of Sterility-The potential for incomplete crimp seals.
View recall details →
Pfizer Inc. recalls Buprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL
Lack of Assurance of Sterility-The potential for incomplete crimp seals.
View recall details →
PFIZER recalls Bleomycin for Injection, USP, 15 units per vial, 1 single do
Presence of particulate matter: glass
View recall details →
Pfizer Inc. recalls 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/
Presence of Particulate Matter; identified as glass
View recall details →
Pfizer Inc. recalls 8.4 % Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/
Presence of Particulate Matter; identified as glass
View recall details →
Pfizer Inc. recalls Atropine Sulfate Injection, USP 1 mg/10 mL (0.1 mg/mL), Life
Presence of Particulate Matter; identified as glass
View recall details →
Pfizer Inc. recalls 2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass A
Presence of Particulate Matter: identified as glass.
View recall details →
Pfizer Inc. recalls 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/m
Presence of Particulate Matter: identified as glass.
View recall details →
Pfizer Inc. recalls 1% Lidocaine HCl Injection, USP, 50mg/5mL(10mg/mL), Glass AB
Presence of Particulate Matter: identified as glass.
View recall details →
Pfizer Inc. recalls MEKTOVI (binimetinib) tablets, 15 mg, 180-count bottle, Rx o
Labeling: Incorrect or Missing Lot and/or Exp Date: The carton and bottle labels state an expiry date of March 2026; the correct expiration date is February 2025.
View recall details →
Pfizer Inc. recalls Vancomycin Hydrochloride for Injection, USP, 1.5 g/vial, Ste
Presence of Particulate Matter: Glass particulate matter detected in injectable.
View recall details →
Pfizer Inc. recalls Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/m
Lack of assurance of sterility: Bags have the potential to leak.
View recall details →
Pfizer Inc. recalls Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 m
Presence of Particulate Matter: A complaint was received for the presence of a hair in one vial.
View recall details →
Pfizer Inc. recalls PROPOFOL Injectable Emulsion, 1 g/100 mL (10 mg/mL), package
Presence of particulate matter
View recall details →
Pfizer Inc. recalls Propofol Injectable Emulsion, 1 g/100 mL (10 mg/mL), package
Presence of particulate matter: particulate identified as a beetle.
View recall details →
Pfizer Inc. recalls Accupril (Quinapril HCl Tablets) 10 mg, 90 Tablets Rx only
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
View recall details →
Pfizer Inc. recalls Accupril (Quinapril HCl Tablets) 20 mg, 90 Tablets, Rx only
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
View recall details →
Pfizer Inc. recalls Accupril (Quinapril HCl Tablets) 40 mg, 90 Tablets, Rx only
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
View recall details →
Pfizer Inc. recalls quinapril and hydrochlorothiazide tablets, 20 mg/25 mg*, 90
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
View recall details →
Pfizer Inc. recalls quinapril HCl/hydrochlorothiazide tablets, 20 mg/12.5 mg*, 9
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
View recall details →
Pfizer Inc. recalls Accuretic (quinapril HCl/hydrochlorothiazide) tablets, 20 mg
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
View recall details →
Pfizer Inc. recalls Accuretic (quinapril HCl/hydrochlorothiazide) Tablets, 10 mg
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
View recall details →
Pfizer Inc. recalls quinapril HCl/hydrochlorothiazide tablets, 20 mg/25 mg*, 90
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
View recall details →
Showing 30 of 134 recalls. See all →